Faculty

Ziad Zoghby, M.D., M.B.A.

Clinical Studies

ACCURACY OF A CUFFLESS PHOTOPLETHYSMOGRAPHY (PPG) CHEST-PATCH MONITOR FOR 24-HOUR AMBULATORY BLOOD PRESSURE MONITORING Scottsdale/Phoenix, AZ Jacksonville, FL Rochester, MN
The purpose of this study is to validate the accuracy and reliability of blood pressure (BP) estimates obtained over 24 hours using a PPG-based chest-patch device compared to the gold standard ambulatory blood pressure monitoring (ABPM) method using an upper arm cuff-based oscillometric BP device, in both hypertensive and normotensive individuals referred by their provider to undergo a 24-hours ABPM for clinical indication.

Autosomal Dominant Polycystic Kidney Disease: Evaluation of Clinical Complications, Pattern of Kidney Function Decline and Identifications of Clinical Variables Related to Disease Progression Rochester, MN
The purpose of this study is to evaluate clinical complications, pattern of kidney function decline and identification of clinical variables related to progression of Autosomal Dominant Polycystic Kidney Disease (ADPKD).

A Double-blind Randomized Parallel Group Study Of The Efficacy And Safety Of Tesevatinib In Subjects With Autosomal Dominant Polycystic Kidney Disease Rochester, MN
The goal of the study is to compare and evaluate safety and efficacy of tesevatinib 50mg versus placebo in patients with ADPKD.
A Phase 1b/2a, Safety, Pharmacokinetic And Dose-Escalation Study Of KD019 In Subjects With Autosomal Dominant Polycystic Kidney Disease Rochester, MN
The primary objective of this study is to determine the safety, plasma pharmacokinetics, and maximum tolerated dose (MTD) of KD019 when administered to subjects with ADPKD.
Renasight Clinical Application, Review And Evaluation (RenaCARE) Study Jacksonville, FL Rochester, MN
The purpose of this study is to evaluate the Renasight™ test, a next generation sequencing (NGS) gene mutation assay, for patients with chronic kidney disease (CKD) which utilizes genomic DNA from patient blood or buccal swab samples to analyze over 300 genes that are associated with autosomal dominant, autosomal recessive and X-linked disorders. Patients undergoing Renasight™ testing are offered optional genetic information sessions in addition to their test results.